At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 153 enrolled
Drug / intervention
fesoterodine fumaratedrug
Likely dose
fesoterodine fumarate 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Long Term Study to Evaluate the Safety, Tolerability and Efficacy of Fesoterodine in Patients With Overactive Bladder.
In Brief
A Phase 3 clinical trial evaluating fesoterodine fumarate for Overactive Bladder. Completed, enrolled 153 participants across 12 sites.
Detailed Summary
To assess the long term safety, tolerability and efficacy of fesoterodine in patients with OAB.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedApr 2008
Primary CompletionAug 2009
TodayJul 2026
First PostedApr 15, 2008
Enrollment StartFeb 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.2 years ago
Interventions
fesoterodine fumaratedrug
4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks